CN117481345B - Chitosan oligosaccharide composition with gastrointestinal regulating function and functional sugar - Google Patents

Chitosan oligosaccharide composition with gastrointestinal regulating function and functional sugar Download PDF

Info

Publication number
CN117481345B
CN117481345B CN202410004945.4A CN202410004945A CN117481345B CN 117481345 B CN117481345 B CN 117481345B CN 202410004945 A CN202410004945 A CN 202410004945A CN 117481345 B CN117481345 B CN 117481345B
Authority
CN
China
Prior art keywords
parts
chitosan
chitosan oligosaccharide
extract
oligosaccharide composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202410004945.4A
Other languages
Chinese (zh)
Other versions
CN117481345A (en
Inventor
李会全
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Ruyuan Technology Co ltd
Original Assignee
Sichuan Ruyuan Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Ruyuan Technology Co ltd filed Critical Sichuan Ruyuan Technology Co ltd
Priority to CN202410004945.4A priority Critical patent/CN117481345B/en
Publication of CN117481345A publication Critical patent/CN117481345A/en
Application granted granted Critical
Publication of CN117481345B publication Critical patent/CN117481345B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention provides a chitosan oligosaccharide composition with a gastrointestinal regulating function and functional sugar, and belongs to the technical field of functional foods for promoting health. The prepared composition comprises chitosan oligosaccharide, chitosan, chinese yam polysaccharide, medlar extract, theanine, mulberry leaf, mulberry, platycodon grandiflorum, mogroside, hawthorn extract, chicken's gizzard-membrane extract and vitamin A and/or citric acid, and can keep low side effect incidence and have good application value under the condition of higher effective rate in gastrointestinal regulation by combining a special production process.

Description

Chitosan oligosaccharide composition with gastrointestinal regulating function and functional sugar
Technical Field
The invention belongs to the technical field of functional foods for promoting health, and particularly relates to a chitosan oligosaccharide composition with a gastrointestinal regulating function and functional sugar.
Background
Chitin is a natural polysaccharide polymer compound mainly derived from animals, and is found in the shells of crustaceans such as shrimps and crabs, the epidermis of insects, and the cell walls of fungi such as mushrooms in nature, and is called "sixth vital element of human body" and "soft gold". After enzymolysis and chemical modification, chitosan and chitosan oligosaccharide with multifunctional biological regulation capacity can be obtained, and the chemical modification logic is as follows: chitin, chitosan deacetylation, chitosan enzymolysis, and chitosan oligosaccharide.
Chitosan and chitosan oligosaccharide have many beneficial biological activities and pharmacological actions, and have important effects on human health. Wherein, the chitosan is a macromolecular structure, is not easy to dissolve in water, can be dissolved in rare organic acid and partial inorganic acid (such as hydrochloric acid), and mainly acts on gastrointestinal tract after being taken, and has multiple functions of reducing blood fat, reducing blood pressure, improving body immunity and the like on human bodies; the chitosan oligosaccharide is small molecular alkaline amino polysaccharide which is easy to dissolve in water, and has free amino and hydroxyl, so that the chitosan oligosaccharide has better biological activity, has the effect of regulating organisms by several times (about 14 times) that of chitosan, and has the effects of resisting bacteria, expelling toxin, regulating cardiovascular and cerebrovascular diseases and the like. The chitosan oligosaccharide is approved as a new food raw material in 2014 in China, can be used in foods (excluding infant foods), is added into foods as a food additive, has the functions of a thickener and a film coating agent, and is listed in GB2760-2014 national food safety Standard food additive use Standard.
Both chitosan and chitosan have positive effects on the gastrointestinal tract, such as promoting healing of digestive tract ulcers, regulating balance of intestinal flora, and the like. However, chitosan and chitosan oligosaccharide are easy to cause sub-health of organisms or pathological protective stress reaction at disease parts, namely side effects, such as emergent symptoms of dry mouth and tongue, dizziness, high excitement, general weakness, nausea, numbness, rash, skin itch and the like. The incidence of side effects after chitosan alone is reported to be about 70%, and the incidence of side effects after chitosan alone is about 4%, which is particularly common for obvious sub-health and middle-aged and elderly people.
So many uncomfortable symptoms appear, and the industrial development of chitosan oligosaccharide and chitosan is seriously affected. Accordingly, there is a need for improvements over the prior art.
Disclosure of Invention
Aiming at the defects existing in the prior art, the invention provides a chitosan oligosaccharide composition with a gastrointestinal regulating function and functional sugar, and aims to solve at least one of the problems, reduce the probability of emergency symptoms after taking as much as possible, reduce the discomfort of people after taking and improve the regulating effect.
In order to achieve the technical purpose, the invention adopts the following technical scheme:
the chitosan oligosaccharide composition with the gastrointestinal regulating function is prepared from the following raw material components in parts by weight:
100-300 parts of chitosan oligosaccharide, 200-400 parts of chitosan, 200-300 parts of Chinese yam polysaccharide, 120-180 parts of medlar extract, 100-120 parts of theanine, 50-80 parts of mulberry, 50-100 parts of platycodon grandiflorum, 20-50 parts of mogroside, 5-30 parts of hawthorn extract, 10-30 parts of chicken's gizzard-membrane extract and 0.2-1.0 part of vitamin A.
The chitosan oligosaccharide composition with the gastrointestinal regulating function is prepared from the following raw material components in parts by weight:
100-300 parts of chitosan oligosaccharide, 200-400 parts of chitosan, 200-300 parts of Chinese yam polysaccharide, 120-180 parts of medlar extract, 100-120 parts of theanine, 50-80 parts of mulberry leaf, 50-80 parts of mulberry, 50-100 parts of platycodon grandiflorum, 20-50 parts of mogroside, 5-30 parts of hawthorn extract, 10-30 parts of chicken's gizzard-membrane extract, 0.2-1.0 part of vitamin A and 40-120 parts of citric acid.
Compared with the prior art, the invention has at least the following beneficial effects:
1. through the synergistic effect of the components of the compatibility of the invention, the vitamin A, the Chinese yam polysaccharide, the medlar extract and other components, the effective effect of the chitosan oligosaccharide composition on constipation, diarrhea and abdominal pain symptoms is ensured, and meanwhile, the occurrence probability of side effects is effectively reduced;
2. the introduction of citric acid can acidify and modify chitosan, so that the probability of side effects during gastrointestinal regulation is further reduced;
3. the specific arrangement mode of the functional sugar ensures that the chitosan oligosaccharide composition can still maintain higher physiological regulation activity and lower occurrence rate of side effects after long-time storage.
Drawings
The accompanying drawings, which are included to provide a further understanding of embodiments of the invention and are incorporated in and constitute a part of this application, illustrate embodiments of the invention. In the drawings:
FIG. 1 is a schematic diagram showing a preferred structure of the chitosan oligosaccharide composition of the invention when it is produced into a functional sugar;
FIG. 2 is a schematic diagram showing another preferred structure of the chitosan oligosaccharide composition of the invention when it is produced as a functional sugar;
wherein, 1-protective layer, 2-first main body layer, 3-isolation layer, 4-second main body layer, 5-vitamin A granule.
Detailed Description
The present invention will be described in further detail with reference to the following examples, for the purpose of making the objects, technical solutions and advantages of the present invention more apparent, and the description thereof is merely illustrative of the present invention and not intended to be limiting.
Example 1
The chitosan oligosaccharide composition with the gastrointestinal regulating function is prepared from the following raw material components in parts by weight:
200 parts of chitosan oligosaccharide, 200 parts of chitosan, 200 parts of Chinese yam polysaccharide, 120 parts of medlar extract, 100 parts of theanine, 50 parts of mulberry leaf, 50 parts of mulberry, 50 parts of platycodon grandiflorum, 20 parts of mogroside, 5 parts of hawthorn extract and 10 parts of chicken's gizzard-membrane extract.
In a first embodiment, the preparation method of the chitosan oligosaccharide composition includes:
step one, material preparation
Preparing raw materials according to raw material components of the chitosan oligosaccharide composition, and crushing non-powdery components (such as platycodon grandiflorum, mulberry leaves and the like) into a predetermined particle size, such as 100-120 meshes; wherein, before pulverizing, non-powdery components such as radix Platycodi, mori fructus, folium Mori, etc. are dried (dried to water content lower than 10%, for example 5%);
step two, wet granulation
Weighing the materials prepared in the first step according to the weight ratio of the raw material components, putting the weighed chitosan oligosaccharide, chitosan, chinese yam polysaccharide, medlar extract, theanine, mulberry leaf, mulberry, platycodon grandiflorum, mogroside, hawthorn extract and chicken's gizzard-membrane extract into a mixer for fully stirring and mixing, adding a proper amount of purified water in the mixing process (preferably, the volume ratio of the raw materials in the mixer to the purified water is 4:1-2:1) to obtain a granulating mixture, and then putting the granulating mixture into a swing granulator to obtain wet granules;
step three, preparing finished product particles:
transferring the wet particles into a vacuum dryer, setting the temperature to be 45-50 ℃, controlling the vacuum degree to be-90 Kpa to-95 Kpa for 30-40 minutes, preparing primary dry particles, and then placing the primary dry particles into a swing granulator for granulating to obtain finished product particles meeting the preset shape and size, namely the prepared chitosan oligosaccharide composition.
Example two
The chitosan oligosaccharide composition with the gastrointestinal regulating function is prepared from the following raw material components in parts by weight:
100 parts of chitosan oligosaccharide, 200 parts of chitosan, 200 parts of Chinese yam polysaccharide, 120 parts of medlar extract, 100 parts of theanine, 50 parts of mulberry leaf, 50 parts of mulberry, 50 parts of platycodon grandiflorum, 20 parts of mogroside, 5 parts of hawthorn extract and 10 parts of chicken's gizzard-membrane extract.
Example III
The chitosan oligosaccharide composition with the gastrointestinal regulating function is prepared from the following raw material components in parts by weight:
300 parts of chitosan oligosaccharide, 200 parts of chitosan, 200 parts of Chinese yam polysaccharide, 120 parts of medlar extract, 100 parts of theanine, 50 parts of mulberry leaf, 50 parts of mulberry, 50 parts of platycodon grandiflorum, 20 parts of mogroside, 5 parts of hawthorn extract and 10 parts of chicken's gizzard-membrane extract.
Example IV
The chitosan oligosaccharide composition with the gastrointestinal regulating function is prepared from the following raw material components in parts by weight:
200 parts of chitosan oligosaccharide, 200 parts of chitosan, 300 parts of Chinese yam polysaccharide, 180 parts of medlar extract, 120 parts of theanine, 80 parts of mulberry leaves, 80 parts of mulberries, 100 parts of platycodon grandiflorum, 50 parts of mogroside, 30 parts of hawthorn extract and 30 parts of chicken's gizzard-membrane extract.
Example five
The chitosan oligosaccharide composition with the gastrointestinal regulating function is prepared from the following raw material components in parts by weight:
200 parts of chitosan oligosaccharide, 400 parts of chitosan, 200 parts of Chinese yam polysaccharide, 120 parts of medlar extract, 100 parts of theanine, 50 parts of mulberry leaf, 50 parts of mulberry, 50 parts of platycodon grandiflorum, 20 parts of mogroside, 5 parts of hawthorn extract and 10 parts of chicken's gizzard-membrane extract.
Example six
The chitosan oligosaccharide composition with the gastrointestinal regulating function is prepared from the following raw material components in parts by weight:
200 parts of chitosan oligosaccharide, 200 parts of chitosan, 200 parts of Chinese yam polysaccharide, 120 parts of medlar extract, 100 parts of theanine, 50 parts of mulberry leaf, 50 parts of mulberry, 50 parts of platycodon grandiflorum, 20 parts of mogroside, 5 parts of hawthorn extract, 10 parts of chicken's gizzard-membrane extract and 0.2 part of vitamin A.
Example seven
The chitosan oligosaccharide composition with the gastrointestinal regulating function is prepared from the following raw material components in parts by weight:
200 parts of chitosan oligosaccharide, 200 parts of chitosan, 200 parts of Chinese yam polysaccharide, 120 parts of medlar extract, 100 parts of theanine, 50 parts of mulberry leaf, 50 parts of mulberry, 50 parts of platycodon grandiflorum, 20 parts of mogroside, 5 parts of hawthorn extract, 10 parts of chicken's gizzard-membrane extract and 0.4 part of vitamin A.
Example eight
The chitosan oligosaccharide composition with the gastrointestinal regulating function is prepared from the following raw material components in parts by weight:
200 parts of chitosan oligosaccharide, 200 parts of chitosan, 200 parts of Chinese yam polysaccharide, 120 parts of medlar extract, 100 parts of theanine, 50 parts of mulberry leaf, 50 parts of mulberry, 50 parts of platycodon grandiflorum, 20 parts of mogroside, 5 parts of hawthorn extract, 10 parts of chicken's gizzard-membrane extract and 0.6 part of vitamin A.
Example nine
The chitosan oligosaccharide composition with the gastrointestinal regulating function is prepared from the following raw material components in parts by weight:
200 parts of chitosan oligosaccharide, 200 parts of chitosan, 200 parts of Chinese yam polysaccharide, 120 parts of medlar extract, 100 parts of theanine, 50 parts of mulberry leaf, 50 parts of mulberry, 50 parts of platycodon grandiflorum, 20 parts of mogroside, 5 parts of hawthorn extract, 10 parts of chicken's gizzard-membrane extract and 1.0 part of vitamin A.
Examples ten
The chitosan oligosaccharide composition with the gastrointestinal regulating function is prepared from the following raw material components in parts by weight:
200 parts of chitosan oligosaccharide, 200 parts of chitosan, 200 parts of Chinese yam polysaccharide, 120 parts of medlar extract, 100 parts of theanine, 50 parts of mulberry leaf, 50 parts of mulberry, 50 parts of platycodon grandiflorum, 20 parts of mogroside, 5 parts of hawthorn extract, 10 parts of chicken's gizzard-membrane extract and 1.5 parts of vitamin A.
In examples two to ten, the preparation method of the chitosan oligosaccharide composition was the same as that of example one (the same procedure, and the weight ratio was changed accordingly).
The chitosan oligosaccharide compositions prepared in examples one to ten were subjected to human test (safety evaluation is carried out before test and is not repeated here), 30 cases were randomly selected for people with symptoms such as constipation, diarrhea and abdominal pain (age at 30-65 years) respectively for test, the dose is 3g each time, 1 time a day, the number of cases, the effective rate and the number of cases and the occurrence rate of side effect reaction which improve the corresponding symptoms after administration are counted, the counting time is 2 months, no other medicine is taken during the period, and the test is stopped immediately once the side effect occurs. In addition, four control groups are provided, namely a chitosan oligosaccharide group (control group I), a chitosan group (control group II), a chitosan oligosaccharide and chitosan group (control group III) and a vitamin group (control group IV), wherein the four control groups take the first embodiment as a reference, and the corresponding components (chitosan oligosaccharide and/or chitosan components) which are equivalent to the total mass of the chitosan oligosaccharide and the chitosan in the first embodiment are taken, specifically, the chitosan oligosaccharide group only takes the chitosan oligosaccharide, and the dosage (about) of each time is 1.2g; the chitosan group only takes chitosan, and the dosage of each time is (about) 1.2g; the chitosan oligosaccharide and the chitosan group are simultaneously tried to eat, and the dosage of each time is 1.2g (about), wherein, the dosage of the chitosan oligosaccharide is 0.6g (about) and the dosage of the chitosan oligosaccharide is 0.6g (about); the vitamin group is a control group IV, which is obtained by adding 2mg of vitamin A based on the control group III, and specific administration effect data are shown in the following table I:
Table one:
wherein a represents the total number of cases of test food, B represents the number of cases of improving the corresponding symptoms (constipation, diarrhea, abdominal distention), C represents the effective rate of improving the corresponding symptoms, D represents the number of cases of discomfort symptoms (side effects) occurring after the test food, E represents the occurrence rate of side effects (for example, in example one, the total number of 30 persons of the test food for constipation, the number of persons occurring side effects after the composition of example one is consumed is 8, so the corresponding occurrence rate of side effects is e=8/30=26.7%, and P represents the average occurrence rate of side effects (for example, 30 persons are selected for the constipation, diarrhea, and abdominal pain, respectively), so the total number of test food is 90 persons, and the number of persons of the constipation, diarrhea, and abdominal pain occurring in the population is 8, 10, and 12 cases, respectively, so the total number of persons of side effects occurring in the 90 persons of example one is 8+10+12=30, and thus p=30/33.3% >, respectively.
As can be seen from Table one, on the stomach intestine which is regulated to have non-organic lesions such as constipation, diarrhea and abdominal pain symptoms, the effective rate of chitosan alone is 63.3%, 30% and 13.3%, and the average occurrence rate of side effects (P) is only 4.4% (see control group one), the effective rate of chitosan alone is 40%, 56.7% and 40%, and the average occurrence rate of side effects (P) is as high as 64.4% (see control group two). After the combination of the two, the effective rates of the traditional Chinese medicine composition for constipation, diarrhea and abdominal pain symptoms are 93.3%, 83.3% and 56.7% (see a control group III) respectively on the stomach and intestine with non-organic lesions, so that the improvement effect on the stomach and intestine functions after the combination is obviously improved, but the side effect still exists (P=44.4%), and the reason is probably that: 1. both materials have side effects; 2. both materials can increase circulation metabolism and act on different cell tissues, and although the occurrence rate of side effects of chitosan oligosaccharide is low when the two materials are used together, the positive signals received by partial sub-healthy or pathological cell tissues are stronger, and the excessive signal stimulus leads to the occurrence of pathological protective adverse reaction, namely side effects.
Therefore, the inventor adopts the Chinese medicine basic theory of five colors entering five zang organs based on the emperor's internal warp theory, and the chitosan oligosaccharide composition of the embodiment one to the embodiment five is formed by compatibility, wherein the Chinese yam polysaccharide corresponds to the five colors entering the white in the five zang organs theory, the mulberry corresponds to black, the mulberry leaf corresponds to green, the theanine corresponds to green, the medlar extract corresponds to red, the hawthorn extract corresponds to red, the fructus momordicae corresponds to yellow, the platycodon grandiflorum corresponds to yellow and the chicken's gizzard membrane extract corresponds to yellow. In addition, the Chinese yam polysaccharide has the effects of tonifying spleen and stomach, regulating immunity, reducing blood sugar, resisting oxidation, resisting aging, resisting tumor and the like, the medlar extract has the effects of nourishing liver and kidney, tonifying essence and improving eyesight, resisting aging, resisting fatigue, reducing blood fat and the like, the theanine has the effects of relieving physical fatigue, protecting nerve cells, assisting in reducing blood pressure, resisting bacteria, resisting inflammation and the like, the mulberry leaf has the effects of clearing lung and moistening dryness, clearing liver and improving vision and the like, and the mulberry has the effects of nourishing yin and blood, promoting the production of body fluid and moisturizing intestine, tonifying liver and kidney and the like, and the momordica grosvenori sweet glycoside has the effects of eliminating phlegm, relieving cough, resisting inflammation and bacteria, protecting liver and the like; the haw extract has the effects of strengthening heart, reducing blood pressure and blood fat, and the chicken's gizzard-membrane extract has the effects of removing food retention and strengthening spleen and stomach (the above are all known components and are not described in detail). After the chitosan oligosaccharide composition of the first to fifth embodiments is formed by matching, it can be found through trial feeding that the occurrence rate of side effects of the matched chitosan oligosaccharide composition is reduced to a certain extent compared with the control group III which only uses chitosan oligosaccharide and chitosan, which is probably because, although the chitosan oligosaccharide and chitosan can activate and repair cells and promote metabolism, the regulation effect of the chitosan oligosaccharide and chitosan on the whole organism is limited, for example, after the chitosan oligosaccharide and chitosan are taken, the activity of dopamine in the organism is increased, the metabolism index is obviously improved, the load of livers, kidneys and the like is greatly increased, and the chitosan and chitosan do not have the function of regulating the load, so that the livers, kidneys and other parts of the body in sub-health or disease states have pathological protective stress reactions, and discomfort symptoms are caused to the testers; the Chinese yam polysaccharide, the medlar extract, the theanine, the mulberry leaf, the mulberry, the platycodon grandiflorum, the mogroside and the like which are compatible in the invention can make up for the defects of chitosan oligosaccharide and chitosan to a certain extent, can play a role in regulating other organs except stomach and intestine, such as liver and the like after being taken, and further reduce side effects after the use of the Chinese yam polysaccharide, the medlar extract, the theanine, the mulberry leaf, the platycodon grandiflorum, the mogroside and the like.
In addition, it can be found from table one that the adjustment of side effects after eating chitosan oligosaccharide and chitosan by the introduction of the Chinese yam polysaccharide, the medlar extract, the theanine, the mulberry leaf, the mulberry, the platycodon grandiflorum, the mogroside, the hawthorn extract, the chicken's gizzard-membrane extract and the like in the examples one to five is very limited, and the effect is not obvious (compared with the three phases of the control group). In the fourth example, the effective rate against constipation, diarrhea and abdominal pain is significantly reduced, although the side effects are low, because in the fourth example, the total ratio of chitosan oligosaccharide and chitosan is reduced, and the ratio of the compatible Chinese yam polysaccharide is increased, so that the actual daily dosage of chitosan oligosaccharide and chitosan is only about 0.44g and 0.44g respectively at the same dosage of 3g, which is compared with 0.6g and 0.6g in the third control group, the dosage is greatly reduced, and the gastrointestinal regulation function of chitosan oligosaccharide and chitosan is also proved from the side.
In further studies, the inventors found that adding a certain amount of vitamin a on the basis of the chitosan oligosaccharide compositions of examples one to five can greatly improve the occurrence of side effects after eating chitosan oligosaccharide and chitosan. It can be seen from table one that vitamin a was not added in examples one to five, and that the average occurrence rate P of side effects after trial feeding was higher (except for example four, whose related description was described above, without reference value) substantially over 20%. In the sixth to tenth embodiments, a certain amount of vitamin a is added based on the first embodiment, and the average occurrence rate of the side effects is reduced and then increased with the increase of the proportion of the vitamin a, but compared with the first to fifth embodiments without vitamin a, the average occurrence rate of the side effects is significantly reduced. The average occurrence rate P of side effects in example ten, which is probably due to the overintake of vitamin a, reaches 18.9% calculated as a 3g dose of the chitosan oligosaccharide composition, was 1.5/(200+200+120+100+50+50+50+20+5+10+1.5) ×3g=1.5/1006.5×3g=4.5 mg, which was already 3mg far from the maximum daily intake recommended for vitamin a, and a part of people developed discomfort symptoms with 2 months of continuous intake, and thus a large part of people who developed side effects in this example ten might be due to the cumulative overintake of vitamin a.
In order to verify the improvement effect of vitamin a on side effects after eating chitosan oligosaccharide and chitosan, the inventor also separately sets a fourth control group, namely 2mg of vitamin a is added on the basis of the third control group, and the combination of the vitamin a, the chitosan, the mulberry fruit extract, the platycodon grandiflorum, the mogroside, the hawthorn fruit extract, the chicken's gizzard-skin extract and the like is not added, so that the vitamin a does not have obvious improvement effect on the side effects at this time through trial feeding, and the effect on constipation, diarrhea and abdominal pain symptoms is reduced, which is probably because when the vitamin a is only used together with the chitosan oligosaccharide and the chitosan: 1. vitamin A, chitosan oligosaccharide and chitosan belong to direct eating, have a certain stimulation effect on the stomach and intestine, and adversely affect the stomach and intestine; 2. the chitosan swells under the action of gastric juice and adheres to gastrointestinal mucosa, so that the absorption of vitamin A is affected; 3. the absorption of vitamin A by the stomach and intestine inhibits the absorption of chitosan oligosaccharide and chitosan to a certain extent, etc.
Based on the above, it is known that the side effects occurring after eating chitosan oligosaccharide and chitosan cannot be significantly improved by directly eating vitamin a, but in the present invention, the side effects after eating chitosan oligosaccharide and chitosan can be improved by combining chitosan oligosaccharide, chitosan, vitamin a, yam polysaccharide, wolfberry extract, theanine, mulberry leaf, mulberry, platycodon root, mogroside, hawthorn extract and chicken's gizzard-membrane extract, which may be due to the following steps: 1. the vitamin A and the components such as the Chinese yam polysaccharide, the medlar extract, the theanine and the like which are used for compatibility have a synergistic effect, so that the regulating effect of each other on the organism is better; 2. the chitosan swelling effect is weakened, the attaching effect is poor or the gastrointestinal mucosa can not be completely covered, so that the absorption influence of the chitosan on the vitamin A is reduced, the vitamin A in the stomach and intestine is fully absorbed, and the promotion effect on the maintenance of the health state of the organism is generated; 3. the components matched with the Chinese medicinal composition can promote or maintain the normal operation of other functional organs of the body, such as the Chinese wolfberry extract for nourishing liver and kidney, mulberry for nourishing liver and kidney, mogroside for protecting liver and resisting inflammation, theanine for clearing lung and moistening dryness, and the like, and the normal operation of the organs effectively reduces the generation of side effects; 4. the components such as the Chinese yam polysaccharide, the medlar extract, the theanine, the mulberry leaf, the mulberry, the platycodon grandiflorum, the mogroside and the like which are used for compatibility have the function of reducing the side effects, and the vitamin A has the catalytic promotion function on the function of reducing the side effects of the other components on the basis of realizing the functions of the components.
In addition, the inventors have also validated other vitamins, such as vitamin B, vitamin C, vitamin D, etc., using similar protocols, but they have not been found to have an ameliorating effect on the above side effects after ingestion, and the details are not described here in detail.
Based on the above, the inventors have further improved that, when chitosan is consumed alone or chitosan and chitosan oligosaccharide are used together, the average occurrence rate P of side effects is high, which is largely due to the fact that chitosan has a relatively large molecular weight and poor water solubility, on the one hand, after entering the stomach and intestine, the absorbed chitosan (little) and/or chitosan oligosaccharide plays a role in enhancing metabolism and consumes water, on the other hand, the non-digested and absorbed chitosan forms colloidal substances under the action of gastric acid, adheres to the stomach and intestine and absorbs a large amount of water at the stomach and intestine, which causes a large amount of dehydration of stomach and intestine cells, and further causes a sick protective adverse reaction, i.e., side effects, such as nausea, vomiting, general weakness, gastrointestinal pain, and the like, of the test person. On this basis, the inventors considered an improvement of chitosan in a composition of chitosan and chitosan oligosaccharide for which citric acid was introduced into the chitosan oligosaccharide composition so that at least part of chitosan in the chitosan oligosaccharide composition was formed as citrated chitosan. The water solubility of the citrated chitosan is greatly improved, after the citrated chitosan is taken, the citrated chitosan can directly absorb water in the oral cavity and other parts and is brought into the stomach and intestine, meanwhile, the citrated chitosan keeps part of the functions of citric acid, can stimulate the oral cavity to secrete saliva and can promote the secretion of gastric acid after being taken, so that after the citrated chitosan is taken, more saliva and gastric acid are used for helping to soften food, improve appetite, promote digestion and metabolism compared with the chitosan which is not subjected to citration, and more water in the oral cavity can be brought into the stomach and intestine, so that the burden of gastrointestinal cells is relieved to a certain extent, the dehydration degree is reduced, and the occurrence probability of discomfort is reduced.
On the basis, the invention provides a chitosan oligosaccharide composition with gastrointestinal regulating function, which is prepared from the following raw material components: chitosan, yam polysaccharide, medlar extract, theanine, mulberry leaf, mulberry, platycodon grandiflorum, mogroside, hawthorn extract, chicken's gizzard-membrane extract, vitamin A and citric acid (specific weight proportions will be discussed below and not described in detail herein), wherein at least a portion of the chitosan is modified by citric acid to form citrated chitosan.
Further, a preparation method of the chitosan oligosaccharide composition is provided, which comprises the following steps:
step one, material preparation
Preparing raw materials according to raw material components of the chitosan oligosaccharide composition, and crushing non-powdery components (such as platycodon grandiflorum, mulberry leaves and the like) into a predetermined particle size, such as 100-120 meshes; wherein, before pulverizing, non-powdery components such as radix Platycodi, mori fructus, folium Mori, etc. are dried (dried to water content lower than 10%, for example 5%);
step two, wet granulation
Weighing the materials prepared in the first step according to the weight ratio required by the raw material components, putting the weighed chitosan oligosaccharide, chitosan, chinese yam polysaccharide, medlar extract, theanine, mulberry leaf, mulberry, platycodon grandiflorum, mogroside, hawthorn extract, chicken's gizzard-skin extract, vitamin A and citric acid into a mixer for fully stirring and mixing, adding a proper amount of purified water in the mixing process (preferably, the volume ratio of the raw materials in the mixer to the purified water is 4:1-2:1) to obtain a granulating mixture, and then putting the granulating mixture into a swing granulator to obtain wet granules;
Step three, preparing dry particles
Transferring the wet particles into a vacuum dryer, setting the temperature to be 45-50 ℃, controlling the vacuum degree to be-90 Kpa to-95 Kpa for 30-40 minutes, preparing first particles, then placing the first particles into a swing granulator for granulation, and obtaining second particles, namely the prepared dry particles (preferably, the granulation is also performed in a vacuum environment, mainly for preventing oxidation of vitamin A);
step four, citric acid acidification modification
Taking a certain amount of absolute ethyl alcohol (for example, 2mL of absolute ethyl alcohol is used for each dry particle, the dosage is determined according to the actual situation), dripping the absolute ethyl alcohol on the surface of the prepared dry particle, standing for a period of time, and waiting for citric acid to modify chitosan (the absolute ethyl alcohol can gradually permeate into the particle after titration to the surface of the dry particle due to the fact that only wet granulation, drying, finishing and other operations are performed in the previous preparation step, so that chitosan in the particle is modified by citric acid); in the step, absolute ethyl alcohol can be titrated for a plurality of times; the whole steps are carried out in a vacuum environment;
Step five, secondary drying
And (3) transferring the chitosan oligosaccharide composition prepared by citric acid acidification modification into a vacuum dryer, wherein the set temperature is between 45 ℃ and 50 ℃, the vacuum degree is controlled between-90 Kpa and-95 Kpa, and the time is 50-60 minutes (prolonged), so that water (generated during citric acid acidification modification for example) and ethanol in the chitosan oligosaccharide composition prepared by citric acid acidification modification are almost completely evaporated, and the dried chitosan oligosaccharide composition modified by citric acid acidification is obtained.
It should be noted that, since citric acid is an acidic organic acid, while chitosan and chitosan are weakly alkaline, the regulation of the body by chitosan and chitosan is dependent on their weakly alkaline to some extent to improve the metabolic environment in vivo, and thus, too much citric acid will adversely affect the efficacy of the chitosan oligosaccharide composition. In addition, although the water solubility of the chitosan oligosaccharide composition after the citric acid acidification modification is greatly improved, the promotion effect of the chitosan oligosaccharide composition on gastrointestinal motility is weakened, so that the substitution degree of the citric acid chitosan product needs to be controlled, namely, the reasonable citric acid dosage needs to be determined. Here, with reference to example eight, a reasonable amount of citric acid was determined, and the weight ratio of citric acid was set as shown in table two:
Watch II (according to weight portion)
Wherein, the numbers 1-5 represent the eleventh embodiment to the fifteenth embodiment respectively.
Based on the proportion in Table II, human body test food tests (safety evaluation is carried out before test food, and is not repeated here) are carried out in a similar manner to the chitosan oligosaccharide compositions prepared in examples I to ten, 100 cases are randomly selected for test food for people with symptoms such as constipation, diarrhea and abdominal pain (age at 30-65 years), the dosage is 3g each time, 1 time each day, the number of cases, the effective rate, the number of cases and the occurrence rate of side effect reaction which play a role in improving the corresponding symptoms after taking are counted, the counting time is 2 months, other medicines are not taken in the period, and the test food is stopped immediately once the side effect occurs. Specific administration effect data are shown in Table III:
table three:
as can be seen from table three, after the chitosan was modified by properly adding citric acid (examples eleven to thirteenth), the chitosan oligosaccharide composition still maintained high effective rate in regulating constipation, diarrhea and abdominal pain symptoms, while the occurrence rate of side effects was further reduced, and in examples twelve and thirteenth, the average occurrence rate of side effects P was even lower than 1%, but as citric acid was increased, the effective rate of the chitosan oligosaccharide composition was gradually reduced and the occurrence rate of side effects was gradually increased (examples fourteen and fifteen).
It should be further noted that, since in the previous solution, both citric acid and vitamin a are formed by stirring, mixing and granulating in a mixer, while citric acid is used for acidifying and modifying chitosan, part (even all) of chitosan oligosaccharide is also acidified and modified, but this is not necessary, because the side effect of chitosan oligosaccharide is relatively low, and this way can lead to an increase in the amount of citric acid, resulting in a decrease in alkalinity and even acidity, and increasing the cost while also producing adverse effects (chitosan oligosaccharide and chitosan depend on weak alkalinity to improve the in vivo metabolic environment). Furthermore, in practical manufacturing processes, the chitosan oligosaccharide composition prepared according to the aforementioned preparation method has a short shelf life, mainly because vitamin a is easily oxidized when exposed to oxygen, which results in a rapid decrease in its regulatory efficacy to the body over time.
Therefore, the invention also provides a chitosan oligosaccharide composition with gastrointestinal regulating function, which is prepared from the following raw material components: the chitosan is modified by citric acid to form citrated chitosan. Further preferably, the sequestering composition comprises starch, gelatin and lecithin (in minor amounts). In this embodiment, the release composition is mainly used to form the release layer 3 (see fig. 1), and the ratio of starch, gelatin and lecithin is the arrangement of the edible glutinous rice paper layer in the prior art, and will not be described in detail herein. Preferably, the isolation composition accounts for 1-2% of the total weight of the chitosan oligosaccharide composition. For example, in a preferred example, in the chitosan oligosaccharide composition, it is prepared by the following raw material components in parts by weight: 200 parts of chitosan oligosaccharide, 200 parts of chitosan, 200 parts of Chinese yam polysaccharide, 120 parts of medlar extract, 100 parts of theanine, 50 parts of mulberry leaf, 50 parts of mulberry, 50 parts of platycodon grandiflorum, 20 parts of mogroside, 5 parts of hawthorn extract, 10 parts of chicken's gizzard-membrane extract, 0.6 part of vitamin A, 100 parts of citric acid and 15 parts of isolation composition.
In a more specific embodiment, the chitosan oligosaccharide composition is used for preparing the functional sugar shown in fig. 1 or 2, referring to fig. 1, the functional sugar is composed of the chitosan oligosaccharide composition and a protective layer 1 coated on the outer side of the chitosan oligosaccharide composition, the chitosan oligosaccharide composition is formed by a first main body layer 2, an isolating layer 3 and a second main body layer 4, wherein the protective layer 1, the first main body layer 2, the isolating layer 3 and the second main body layer 4 are sequentially coated from outside to inside, the isolating layer 3 is prepared from the isolating composition, the protective layer 1 is a chitosan coating layer, the first main body layer 2 is prepared by mixing chitosan, yam polysaccharide, medlar extract, theanine, mulberry leaf, balloonflower root, mogroside, hawthorn fruit extract, extract and citric acid, and the second main body layer 4 is prepared by mixing chitosan oligosaccharide, yam polysaccharide, medlar extract, theanine, mulberry leaf, balloonflower root, stevioside, hawthorn fruit extract and vitamin A. Preferably, the weights of the chitosan oligosaccharide, the yam polysaccharide, the medlar extract, the theanine, the mulberry leaf, the mulberry, the platycodon grandiflorum, the mogroside, the hawthorn extract and the chicken's gizzard-membrane extract in the first main body layer 2 and the second main body layer 4 are respectively basically equivalent.
Preferably, the protective layer 1 accounts for 1-2% of the total weight of the functional sugar. Since the chitosan in the protective layer 1 occupies less of the whole functional sugar, the effect on the whole effect of the chitosan oligosaccharide composition in the protective layer 1 is less (almost none), so the produced functional sugar is basically the effect of the chitosan oligosaccharide composition, and the chitosan coating layer can effectively resist water and moisture, which is very beneficial to maintaining the effect of the internal chitosan oligosaccharide composition.
Further, the embodiment also provides a preparation method of the functional sugar, which specifically comprises the following steps:
step S1, material preparation
S11, preparing raw materials according to raw material components of the chitosan oligosaccharide composition, and crushing non-powdery components (such as platycodon grandiflorum, mulberries, mulberry leaves and the like) in the raw material components to a preset particle size, for example, 100-120 meshes; wherein, before pulverizing, non-powdery components such as radix Platycodi, mori fructus, folium Mori, etc. are dried (dried to water content lower than 10%, for example 5%);
s12, weighing the materials prepared in the step S11 according to the weight ratio required by the raw material components, uniformly mixing the Chinese yam polysaccharide, the medlar extract, theanine, the mulberry leaf, the mulberry, the platycodon grandiflorum, the mogroside, the hawthorn extract and the chicken' S gizzard-membrane extract, and then equally dividing the mixture into two parts for standby, wherein the first mixture and the second mixture are calculated;
S13, preparation of coating liquid
According to the material prepared in the step S11, a certain amount (determined according to actual needs) of chitosan is weighed and dissolved in acetic acid solution with the mass fraction of 0.5%, glycerin (about 20% of the weight of the chitosan weighed in the step) and tween 80 (0.5% of the total weight of the acetic acid solution) are added, and the chitosan coating solution with the mass concentration of 1.5% is prepared for standby;
step S2, granulating the chitosan oligosaccharide composition
S21, second body layer 4 is formed:
uniformly mixing the first mixture with chitosan oligosaccharide and vitamin A (for example, by stirring), adding a proper amount of purified water in the mixing process (the volume ratio of the material to the water is 4:1-2:1), then putting the mixture into a swing granulator to obtain wet particles, transferring the wet particles into a vacuum dryer for drying, and cooling in a vacuum environment;
s22 formation of isolation layer 3
Mixing starch, gelatin and lecithin in proportion, preparing into thin slurry, filtering out impurities, then preparing into starch paste by hot water, then uniformly spraying the starch paste on the surface of the second main body layer 4 formed in the step S21 (in a spraying cavity which is arranged independently), and drying in a vacuum dryer;
s23, first body layer 2 formation
Uniformly mixing the second mixture with chitosan and citric acid (for example, by stirring), adding a proper amount of absolute ethyl alcohol (specific proportion can be adjusted according to the previous material water volume ratio) in the mixing process to obtain wet materials, uniformly smearing the wet materials on the outer surface of the isolation layer 3, transferring the wet materials into a vacuum dryer again for drying, completely volatilizing the ethyl alcohol therein, repeatedly smearing and drying until the requirements are met, and preliminarily forming a blank of the first main body layer 2; then, taking a certain amount of absolute ethyl alcohol (specifically determined according to actual conditions), dripping the absolute ethyl alcohol on the surface of the blank, soaking the first main body layer 2, keeping the state for 2-3 hours, and then drying (optionally performing granule finishing operation);
in this step, due to the arrangement of the isolation layer 3, the absolute ethyl alcohol cannot penetrate through the isolation layer 3, so that citric acid cannot affect the chitosan oligosaccharide at the second main body layer 4, the effect of reducing side effects and the like can be realized under the condition of using less citric acid (the mixture ratio of the eleventh embodiment and the twelfth embodiment is enough), and adverse effects are avoided; in addition, when the second mixture is mixed with chitosan and citric acid, the dosage of the absolute ethyl alcohol is limited, and the time is short, so that the proportion of the chitosan component which is modified by citric acid is small, and the citric acid is quite insufficient, and therefore, the subsequent titration and soaking treatment of the absolute ethyl alcohol is carried out;
S3, coating treatment
And (3) coating the functional sugar in a coating pot by using the coating liquid prepared in the step (S13) until the thickness of the coating film reaches the preset requirement, and curing at 50 ℃ for 0.5h to obtain the finished functional sugar.
In another alternative, the vitamin a may be prepared in advance as granules and dispersed in the second body layer 4, see vitamin a granules 5 in fig. 2.
By actual use comparison, the chitosan oligosaccharide composition prepared only through the steps of preparing dry particles, acidifying and modifying citric acid and drying secondarily is placed in a ventilated and dry environment, the efficacy of the chitosan oligosaccharide composition on gastrointestinal regulation is gradually weakened along with the extension of time, and the chitosan oligosaccharide composition is used after being stored for 3 months, so that the side effect generation rate is far beyond that of the data of the experimental food test stage. By the preparation method of the functional sugar, the side effect generation rate is still lower after the functional sugar is stored for 2 years under the same storage condition, and the side effect generation rate is basically consistent with that of the food test stage. Part of this is because the citric acid used has an antioxidant effect itself and can maintain the active ingredients in the functional sugar without deterioration, while vitamin a is provided in the second main body layer 4 and is hardly oxidized by oxygen outside the functional sugar; the arrangement of the protective layer 1 effectively reduces the possibility of water absorption of the functional sugar.
Finally, it is further noted that relational terms such as "first" and "second", and the like, are used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Moreover, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to the embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims (5)

1. The chitosan oligosaccharide composition with the gastrointestinal regulating function is characterized by being prepared from the following raw material components in parts by weight:
100-300 parts of chitosan oligosaccharide, 200-400 parts of chitosan, 200-300 parts of Chinese yam polysaccharide, 120-180 parts of medlar extract, 100-120 parts of theanine, 50-80 parts of mulberry leaf, 50-80 parts of mulberry, 50-100 parts of platycodon grandiflorum, 20-50 parts of mogroside, 5-30 parts of hawthorn extract, 10-30 parts of chicken's gizzard-membrane extract, 0.2-1.0 part of vitamin A and 40-120 parts of citric acid;
wherein at least a portion of the chitosan in the chitosan oligosaccharide composition is formed as citrated chitosan;
the preparation method of the chitosan oligosaccharide composition comprises the following steps:
step one, material preparation
Preparing raw materials according to the raw material components of the chitosan oligosaccharide composition, and crushing non-powdery components in the raw materials to a preset particle size;
step two, wet granulation
Weighing the materials prepared in the first step according to the weight ratio required by the raw material components, putting the weighed chitosan oligosaccharide, chitosan, chinese yam polysaccharide, medlar extract, theanine, mulberry leaf, mulberry, platycodon grandiflorum, mogroside, hawthorn extract, chicken's gizzard-skin extract, vitamin A and citric acid into a mixer, fully stirring and mixing, adding a proper amount of purified water in the mixing process to obtain a granulating mixture, and then putting the granulating mixture into a swing granulator to obtain wet granules;
Step three, preparing dry particles
Transferring the wet particles into a vacuum dryer, setting the temperature to be 45-50 ℃, controlling the vacuum degree to be-90 Kpa to-95 Kpa for 30-40 minutes, preparing first particles, and then placing the first particles into a swing granulator for granulating to obtain second particles, namely the prepared dry particles;
step four, citric acid acidification modification
Taking a certain amount of absolute ethyl alcohol, dripping the absolute ethyl alcohol on the surfaces of the prepared dry particles, standing for a period of time, and waiting for citric acid to acidify and modify chitosan;
step five, secondary drying
And (3) transferring the chitosan oligosaccharide composition prepared by citric acid acidification modification into a vacuum dryer, setting the temperature to be 45-50 ℃, and controlling the vacuum degree to be between-90 Kpa and-95 Kpa for 50-60 minutes, so that almost all water and ethanol in the chitosan oligosaccharide composition prepared by citric acid acidification modification are evaporated, and obtaining the dried chitosan oligosaccharide composition modified by citric acid acidification.
2. The functional sugar with the gastrointestinal regulating function is characterized by comprising a chitosan oligosaccharide composition and a protective layer (1) coated on the outer side of the chitosan oligosaccharide composition, wherein the chitosan oligosaccharide composition is prepared from the following raw material components in parts by weight: 100-300 parts of chitosan oligosaccharide, 200-400 parts of chitosan, 200-300 parts of Chinese yam polysaccharide, 120-180 parts of medlar extract, 100-120 parts of theanine, 50-80 parts of mulberry, 50-100 parts of platycodon grandiflorum, 20-50 parts of mogroside, 5-30 parts of hawthorn extract, 10-30 parts of chicken's gizzard-membrane extract, 0.2-1.0 part of vitamin A, 40-120 parts of citric acid and an isolation composition, wherein the isolation composition accounts for 1-2% of the total weight of the chitosan oligosaccharide composition; at least a portion of the chitosan in the chitosan oligosaccharide composition is formed as citrated chitosan;
The chitosan oligosaccharide composition is formed by a first main body layer (2), an isolation layer (3) and a second main body layer (4), wherein the protection layer (1), the first main body layer (2), the isolation layer (3) and the second main body layer (4) are sequentially arranged in a wrapping mode from outside to inside, the isolation layer (3) is made of the isolation composition, the protection layer (1) is a chitosan coating layer, the first main body layer (2) is made by mixing chitosan, chinese yam polysaccharide, medlar extract, theanine, mulberry leaf, mulberry, platycodon grandiflorum, mogroside, hawthorn extract, chicken's gizzard-membrane extract and citric acid, and the second main body layer (4) is made of chitosan oligosaccharide, chinese yam polysaccharide, medlar extract, theanine, mulberry leaf, mulberry, platycodon grandiflorum, mogroside, hawthorn extract, chicken's gizzard-membrane extract and vitamin A.
3. A functional sugar with gastrointestinal regulating function according to claim 2, wherein said sequestering composition comprises starch, gelatin and lecithin.
4. A functional sugar with gastrointestinal regulating function according to claim 2, wherein the chitosan oligosaccharide composition is prepared by the following raw material components:
200 parts of chitosan oligosaccharide, 200 parts of chitosan, 200 parts of Chinese yam polysaccharide, 120 parts of medlar extract, 100 parts of theanine, 50 parts of mulberry leaf, 50 parts of mulberry, 50 parts of platycodon grandiflorum, 20 parts of mogroside, 5 parts of hawthorn extract, 10 parts of chicken's gizzard-membrane extract, 0.6 part of vitamin A, 100 parts of citric acid and 15 parts of isolation composition.
5. A process for the preparation of a functional sugar according to any one of claims 2 to 4, comprising the specific steps of:
step S1, material preparation
S11, preparing raw materials according to raw material components of the chitosan oligosaccharide composition, and crushing non-powdery components in the raw material to a preset particle size;
s12, weighing the materials prepared in the step S11 according to the weight ratio required by the raw material components, uniformly mixing the Chinese yam polysaccharide, the medlar extract, theanine, the mulberry leaf, the mulberry, the platycodon grandiflorum, the mogroside, the hawthorn extract and the chicken' S gizzard-membrane extract, and then equally dividing the mixture into two parts for standby, wherein the first mixture and the second mixture are calculated;
s13, preparation of coating liquid
According to the material prepared in the step S11, a certain amount of chitosan is weighed and dissolved in acetic acid solution with the mass fraction of 0.5%, glycerol and Tween 80 are added, and the chitosan coating solution with the mass concentration of 1.5% is prepared for standby;
Step S2, granulating the chitosan oligosaccharide composition
S21, forming a second main body layer (4):
uniformly mixing the first mixture with chitosan oligosaccharide and vitamin A, adding a proper amount of purified water in the mixing process, then putting the mixture into a swing granulator to obtain wet granules, transferring the wet granules into a vacuum dryer for drying, and cooling in a vacuum environment;
s22, formation of isolation layer (3)
Preparing the isolating composition into a starch paste by hot water, uniformly spraying the starch paste on the surface of the second main body layer (4) formed in the step S21, and drying in a vacuum dryer;
s23, forming a first main body layer (2)
Uniformly mixing the second mixture with chitosan and citric acid, adding a proper amount of absolute ethyl alcohol in the mixing process to obtain wet materials, uniformly coating the wet materials on the outer surface of the isolation layer (3), transferring the wet materials into a vacuum dryer again for drying, completely volatilizing the ethanol in the wet materials, repeatedly coating and drying until the requirements are met, and preliminarily forming a blank body of the first main body layer (2); then, a certain amount of absolute ethyl alcohol is taken and is dripped on the surface of the embryo body, the first main body layer (2) is soaked, and after the state is kept for 2-3 hours, drying treatment is carried out, so that the embryo body is obtained;
S3, coating treatment
And (3) coating the functional sugar in a coating pot by using the coating liquid prepared in the step (S13) until the thickness of the coating film reaches the preset requirement, and curing at 50 ℃ for 0.5h to obtain the finished functional sugar.
CN202410004945.4A 2024-01-03 2024-01-03 Chitosan oligosaccharide composition with gastrointestinal regulating function and functional sugar Active CN117481345B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410004945.4A CN117481345B (en) 2024-01-03 2024-01-03 Chitosan oligosaccharide composition with gastrointestinal regulating function and functional sugar

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202410004945.4A CN117481345B (en) 2024-01-03 2024-01-03 Chitosan oligosaccharide composition with gastrointestinal regulating function and functional sugar

Publications (2)

Publication Number Publication Date
CN117481345A CN117481345A (en) 2024-02-02
CN117481345B true CN117481345B (en) 2024-04-05

Family

ID=89683464

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202410004945.4A Active CN117481345B (en) 2024-01-03 2024-01-03 Chitosan oligosaccharide composition with gastrointestinal regulating function and functional sugar

Country Status (1)

Country Link
CN (1) CN117481345B (en)

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07236419A (en) * 1994-02-25 1995-09-12 Fuji Kenko Kenkyukai:Kk Tea composition for promoting health
JP2006187258A (en) * 2005-01-07 2006-07-20 Nisshin Pharma Inc IMMUNE STRENGTH AMELIORATING FOOD CONTAINING beta-GLUCAN DERIVED FROM BAKER'S YEAST
WO2010142400A2 (en) * 2009-06-10 2010-12-16 Arivine Pharma Ag Chitosan oligosaccharide-based compositions
CN102470142A (en) * 2009-07-28 2012-05-23 株式会社爱茉莉太平洋 Composition containing chitooligosaccharide for recovering from fatigue
CN103783509A (en) * 2013-12-31 2014-05-14 陈慧婷 Endothelium corneum gigeriae galli-yam dispersible tablet and preparation method thereof
CN105595308A (en) * 2015-11-27 2016-05-25 青岛银色世纪健康产业集团有限公司 Chitosan oligosaccharide composite powder with adjuvant hpyerglycemic function and preparation method thereof
CN105639339A (en) * 2015-12-29 2016-06-08 珠海市金隆生物科技有限公司 Fatigue-resistance and immunity-enhancement chitosan oligosaccharide beverage and preparation method thereof
CN106820151A (en) * 2016-12-22 2017-06-13 北京康比特体育科技股份有限公司 A kind of bivalve compound health composition, preparation method and application
CN107223752A (en) * 2016-08-05 2017-10-03 青岛壳寡糖生物科技有限公司 A kind of chitosan oligosaccharide promotees the pressed candy of gastrointestinal disturbances absorption function
CN108065153A (en) * 2017-12-22 2018-05-25 安徽谷优美食品科技有限公司 A kind of preparation method of nutrition and health care mulberries purple potato drink
CN108094715A (en) * 2018-01-18 2018-06-01 青岛博智汇力生物科技有限公司 A kind of composition and its application
CN108157971A (en) * 2018-02-08 2018-06-15 沈勇子 A kind of chitosan oligosaccharide liquid oral medicine and preparation method thereof
CN109170104A (en) * 2018-11-21 2019-01-11 秦皇岛惠恩生物技术有限公司 Turmeric pressed candy and preparation method thereof
CN109480132A (en) * 2018-11-08 2019-03-19 湖北铭泰健康科学有限公司 A kind of liquid healthy beverage and its preparation method and application containing chitosan oligosaccharide
CN110025743A (en) * 2019-05-21 2019-07-19 广西本草坊保健品有限公司 A kind of Chinese herbal medicine granule and preparation method thereof adjusting children's stomach
CN112544977A (en) * 2020-11-03 2021-03-26 国家粮食和物资储备局科学研究院 Preparation method of multi-layer coated probiotic microcapsule
CN113243532A (en) * 2021-06-10 2021-08-13 曲阜师范大学 Natural gel of dietary supplement capable of improving irritable bowel syndrome and preparation method thereof
CN114343180A (en) * 2022-01-25 2022-04-15 山东安然纳米实业发展有限公司 A series of compositions with effects of clearing hollow viscera and removing toxic substance, and its application

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07236419A (en) * 1994-02-25 1995-09-12 Fuji Kenko Kenkyukai:Kk Tea composition for promoting health
JP2006187258A (en) * 2005-01-07 2006-07-20 Nisshin Pharma Inc IMMUNE STRENGTH AMELIORATING FOOD CONTAINING beta-GLUCAN DERIVED FROM BAKER'S YEAST
WO2010142400A2 (en) * 2009-06-10 2010-12-16 Arivine Pharma Ag Chitosan oligosaccharide-based compositions
CN102470142A (en) * 2009-07-28 2012-05-23 株式会社爱茉莉太平洋 Composition containing chitooligosaccharide for recovering from fatigue
CN103783509A (en) * 2013-12-31 2014-05-14 陈慧婷 Endothelium corneum gigeriae galli-yam dispersible tablet and preparation method thereof
CN105595308A (en) * 2015-11-27 2016-05-25 青岛银色世纪健康产业集团有限公司 Chitosan oligosaccharide composite powder with adjuvant hpyerglycemic function and preparation method thereof
CN105639339A (en) * 2015-12-29 2016-06-08 珠海市金隆生物科技有限公司 Fatigue-resistance and immunity-enhancement chitosan oligosaccharide beverage and preparation method thereof
CN107223752A (en) * 2016-08-05 2017-10-03 青岛壳寡糖生物科技有限公司 A kind of chitosan oligosaccharide promotees the pressed candy of gastrointestinal disturbances absorption function
CN106820151A (en) * 2016-12-22 2017-06-13 北京康比特体育科技股份有限公司 A kind of bivalve compound health composition, preparation method and application
CN108065153A (en) * 2017-12-22 2018-05-25 安徽谷优美食品科技有限公司 A kind of preparation method of nutrition and health care mulberries purple potato drink
CN108094715A (en) * 2018-01-18 2018-06-01 青岛博智汇力生物科技有限公司 A kind of composition and its application
CN108157971A (en) * 2018-02-08 2018-06-15 沈勇子 A kind of chitosan oligosaccharide liquid oral medicine and preparation method thereof
CN109480132A (en) * 2018-11-08 2019-03-19 湖北铭泰健康科学有限公司 A kind of liquid healthy beverage and its preparation method and application containing chitosan oligosaccharide
CN109170104A (en) * 2018-11-21 2019-01-11 秦皇岛惠恩生物技术有限公司 Turmeric pressed candy and preparation method thereof
CN110025743A (en) * 2019-05-21 2019-07-19 广西本草坊保健品有限公司 A kind of Chinese herbal medicine granule and preparation method thereof adjusting children's stomach
CN112544977A (en) * 2020-11-03 2021-03-26 国家粮食和物资储备局科学研究院 Preparation method of multi-layer coated probiotic microcapsule
CN113243532A (en) * 2021-06-10 2021-08-13 曲阜师范大学 Natural gel of dietary supplement capable of improving irritable bowel syndrome and preparation method thereof
CN114343180A (en) * 2022-01-25 2022-04-15 山东安然纳米实业发展有限公司 A series of compositions with effects of clearing hollow viscera and removing toxic substance, and its application

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
壳聚糖及壳聚糖-柠檬酸结构性质和功能性质的比较;崔文慧;郭芹;李庆鹏;靳婧;哈益明;;食品科学;20160623;第38卷(第05期);第134-141页 *
壳聚糖的体内生物活性功能研究进展;覃彩芹, 池伟林, 舒海波;孝感学院学报;20041230(第06期);第5-9页 *
孙晖.《现代生物学进展》.长春：吉林大学出版社,2001,第55页. *
徐怀德.《天然产物提取工艺学》.北京：中国轻工业出版社,2006,第96页. *
柠檬酸化壳聚糖的合成及其水溶性研究;孙晓君;刘晓慧;秦智;冯玉杰;;哈尔滨工业大学学报;20110630(第06期);第145页摘要、左栏第1段、第146页第1.3节 *
柠檬酸改性壳聚糖水凝胶的制备与性能;杨上莹;袁卉华;易兵成;王先流;周颖;张彦中;;功能高分子学报;20180525;第31卷(第03期);第232-240页 *
王淼.《食品生物化学》.北京：中国轻工业出版社,2020,第41页. *
阿魏酸/壳聚糖交联的研究进展;李辰;李坚斌;;食品工业;20160220;第37卷(第02期);第220-23页 *

Also Published As

Publication number Publication date
CN117481345A (en) 2024-02-02

Similar Documents

Publication Publication Date Title
CN103461631A (en) Tea sugar food and making method thereof
CN109549097A (en) A kind of health caring noodles with functions of reducing sugar and reducing fat
CN113115940A (en) Heart calming and sleep aiding composition as well as preparation method and application thereof
WO2016163652A1 (en) Health supplement food for promotion of hair growth, mitigation and alleviation of hair loss, regulation of blood glucose, and alleviation and relief of gastric disorder symptoms
CN106465946A (en) A kind of loosening bowel to relieve constipation dietary fiber
CN117562257A (en) High-fat low-carbon food composition and preparation method thereof
CN117481345B (en) Chitosan oligosaccharide composition with gastrointestinal regulating function and functional sugar
CN109123351A (en) A kind of special doctor's food and preparation method with hyperglycemia population generation meal regulatory function
CN103404725B (en) Wheat type 18 to 46-day-old piggy feed and preparation method thereof
WO2005074952A1 (en) Chinese medicine for treatment of irritable bowel sysndrome and the preparation thereof
EP0868917B1 (en) Use of stevia extracts for the manufacture of an antihistaminic composition
CN109999117A (en) Prevent and treat enteritis, bacillary dysentery, dysentery, intractable diarrhea Chinese medicine composition
CN115137068A (en) Composition for reducing uric acid and application thereof
CN110037153A (en) A kind of fructus arctii Moringa pressed candy
CN107594526A (en) A kind of algin is the preparation method of the aid digestion soft capsule preparation of capsule material
KR100504124B1 (en) Mixture for prevention of obesity
CN112806504A (en) Beverage capable of repairing digestive function and maintaining beauty and keeping young and preparation method thereof
CN110507707A (en) A kind of Chinese medicine composition and preparation method thereof for treating type II diabetes
CN104825379A (en) Whitening peeling night cream capable of reducing melanin deposition and preparation method thereof
CN110839825A (en) Preparation method of coarse cereal hollow noodles
CN109480096A (en) A kind of pet tablet and preparation method thereof of enriching blood
CN114568557B (en) Ginseng polysaccharide sweet golden flower black tea and preparation method thereof
CN111053815B (en) Traditional Chinese medicine composition for preventing acute gastric ulcer and preparation method thereof
CN113632903B (en) Turbid-discharging and beautifying composition and preparation process thereof
KR102513673B1 (en) Manufacturing method of acupuncture pills

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant